Anesthesia Drugs Market Size
|Study Period||2018 - 2028|
|Market Size (2023)||USD 7.02 Billion|
|Market Size (2028)||USD 8.29 Billion|
|CAGR (2023 - 2028)||3.40 %|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anesthesia Drugs Market Analysis
The Global Anesthesia Drugs Market size is expected to grow from USD 7.02 billion in 2023 to USD 8.29 billion by 2028, at a CAGR of 3.40% during the forecast period (2023-2028).
Due to the emergence of the pandemic situation, demand for anesthesia drugs decreased slightly in 2020, resulting in surgeries being postponed or canceled. According to a study published in the British Journal of Surgery in May 2020, around 28.4 million elective surgeries worldwide were estimated to be canceled or postponed, based on 12 weeks of peak disruption to hospital services due to COVID-19. However, as activities resume, all of the elective surgeries that had been postponed are now being completed, increasing anesthesia drug consumption.
The primary factors propelling the growth of this market are the rising number of surgeries and new anesthesia drug approvals. According to the American Society of Plastic Surgeons, in 2020, 2.3 million cosmetic surgical procedures, 13.2 million cosmetic minimally invasive procedures, and 6.8 million reconstructive procedures were performed in the United States 2020, representing a 3% increase over 2019. This indicates the rising number of surgeries, which ultimately results in the rising demand for anesthesia drugs.
Moreover, according to the article 'Trauma of Major Surgery' published in the National Center for Biotechnology Information (NCBI) in July 2020, globally, a staggering 310 million major surgeries are performed each year. Similarly, according to the article titled 'Incidence and Cumulative Risk of Major Surgery in Older Persons in the United States published in July 2021, in the United States, Nearly nine major surgeries were performed annually for every 100 older persons, and more than 1 in 7 Medicare beneficiaries underwent a major surgery over five years, representing nearly 5 million unique older people.
Furthermore, the development and approvals of novel local anesthesia drugs are proving to be a new revenue-generating resource for market players. For instance, in February 2021, PainPass launched the first Cannabidiol (CBD)/lidocaine product line targeting those with chronic pain and for numbing muscles externally. In December 2021, Hikma Pharmaceuticals PLC (Hikma), has launched Bupivacaine HCl Injection, USP through its United States affiliate, Hikma Pharmaceuticals United States Inc. The company has launched 0.25%, 0.5% and 0.75% in 10mL and 30mL doses. Moreover, in June 2021, PAION AG received United Kingdom Medicines & Healthcare products Regulatory Agency (MHRA) approval for Byfavo (remimazolam besylate) in adults for procedural sedation.
Thus, all aforementioned factors, such as the increasing number of surgical procedures and product launches, boost the market over the forecast period.
Anesthesia Drugs Market Trends
This section covers the major market trends shaping the Anesthesia Drugs Market according to our research experts:
The Propofol Segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment
Propofol is one of the most commonly used general anesthetics in surgeries and is used as a sedative for critical care (including those with COVID-19) in the ICU. It is used for the initiation and maintenance of procedural sedation, general anesthesia, etc. In June 2020, the United States Food & Drug Administration approved the use of Fresenius Propoven 2% emulsion to maintain sedation in COVID-19 patients (16 years and above) requiring mechanical ventilation.
Propofol is also used for the induction maintenance of anesthesia and the management of refractory status epilepticus. The drug has been used for a long time for various types of surgical procedures that require anesthesia. The companies that manufacture propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi.
Furthermore, as per the study published in the British Journal of anesthesiology in May 2021, titled "Surgical activity in England and Wales during the COVID-19 pandemic: a nationwide observational cohort study", the total number of surgical procedures carried out in England and Wales in 2020 was 3,102,674. Hence, the increasing incidences of emergency surgeries, extensive usage of the drug, short-acting characteristics, and a rising number of surgical procedures worldwide are the major factors propelling the growth of the market.
As a result of the aforementioned factors, the propofol segment is expected to experience healthy growth during the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period
North America currently dominates the anesthesia drugs market and is expected to continue its stronghold for a few more years. The United States is the largest regional market in the world. With the emergence of COVID-19, the United States faced heavy shortages of vital anesthesia drugs, particularly dexmedetomidine, midazolam, propofol, and neuromuscular blocking agents. As a result, many companies are ramping up their production of anesthesia drugs. For instance, in May 2020, Hikma Pharmaceutical introduced a new product, "Propofol Injectable Emulsion," in the United States.
Furthermore, this market is driven by the increasing number of surgeries, rising aging population with increasing chronic conditions, and advancements in anesthesia technologies. according to the American Society of Plastic Surgeons (ASPS), in 2020, about 768,000 total cosmetic procedures were performed in people aged 10-29 years, and 6.1 million total cosmetic procedures were performed among the age group of 40-54-year-olds. These statistics indicate that surgical procedures are constantly increasing in the region, ultimately driving the demand for anesthesia drugs. The application of anesthetics in general surgeries is expected to contribute significantly to the growth of the market.
Moreover, new anesthesia drugs are being developed in the country, which is expected to propel market growth. For instance, in June 2020, Medova and the New York School of Regional Anesthesia (NYSORA) entered a partnership to introduce SAFIRA (SAFer Injection for Regional Anesthesia) in the United States. Also, in January 2020, the Food & Drug Administration approved the new drug application for cocaine hydrochloride (HCI; NUMBRINO) nasal solution 4% (40 mg/mL), manufactured by Lannett Company, for anesthetic use in the United States. Moreover, in December 2021, Hikma Pharmaceuticals PLC (Hikma) launched Bupivacaine HCl Injection USP through its United States affiliate Hikma Pharmaceuticals USA Inc. The company launched 0.25%, 0.5%, and 0.75% in 10 milliliter and 30 milliliter doses. Similarly, in April 2020, Blue-Zone Technologies Ltd received approval from Health Canada for desflurane, USP, an anesthetic drug used for general anesthesia.
Such developments coupled with growth in the number of surgeries using anesthesia drugs are anticipated to bolster market growth in the region.
To understand geography trends, Download Sample Report
Anesthesia Drugs Industry Overview
The anesthesia drugs market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with rising drug approvals, mid-size to smaller companies are expanding their market presence by introducing new ingredients at fewer prices. Companies like Baxter, Abbott Laboratories, Aspen, Fresenius SE, Roche, and B. Braun Melsungen AG hold substantial market shares in the anesthesia drugs market.
Anesthesia Drugs Market Leaders
Baxter International Inc.
Aspen Pharmacare Holdings Limited
B. Braun Melsungen AG
Fresenius SE & Co. KGaA
*Disclaimer: Major Players sorted in no particular order
Anesthesia Drugs Market News
- In January 2022, Laboratoires Théa SAS (Théa) entered an agreement to purchase seven branded ophthalmic products from Akorn Operating Company LLC. The strategic move will enable Théa to add Akorn branded products to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures.
- In February 2022, Sedana Medical AB announced the launch of Sedaconda (isoflurane) in Germany. Sedaconda (isoflurane) received European DCP approval in July 2021. Also, the product has received national approvals in 14 countries. Additional applications for marketing approval have been submitted in the same year, and in 2022, the company is expected to receive national approvals in Italy, Poland, Switzerland, and the United Kingdom.
Anesthesia Drugs Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 New Approvals of Anesthesia Drugs
4.2.3 Reduction in the Cost of Newly Invented Drugs
4.3 Market Restraints
4.3.1 Side Effects of General Anesthetics
4.3.2 Lack of Skilled Anesthetics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug Type
5.1.1 General Anesthesia Drugs
18.104.22.168 Other General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
22.214.171.124 Other Local Anesthesia Drugs
5.2 By Route of Administration
5.2.3 Other Routes of Administration
5.3 By Application
5.3.1 General Surgery
5.3.2 Plastic Surgery
5.3.3 Cosmetic Surgery
5.3.4 Dental Surgery
5.3.5 Other Applications
5.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle-East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Apsen Pharmacare Holdings Limited
6.1.3 Baxter International Inc.
6.1.4 B. Braun Melsungen AG
6.1.5 Fresenius SE & Co. KGaA
6.1.6 Pfizer Inc.
6.1.7 Teva Pharmaceutical Industries Limited
6.1.8 Dr. Reddy's Laboratories
6.1.9 Abbott Laboratories Inc.
6.1.10 Novartis AG
6.1.11 Eisai Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Anesthesia Drugs Market Research FAQs
How big is the Global Anesthesia Drugs Market?
The Global Anesthesia Drugs Market size is expected to reach USD 7,015.30 million in 2023 and grow at a CAGR of 3.40% to reach USD 8,291.80 million by 2028.
What is the current Global Anesthesia Drugs Market size?
In 2023, the Global Anesthesia Drugs Market size is expected to reach USD 7,015.30 million.
Who are the key players in Global Anesthesia Drugs Market?
Baxter International Inc., Aspen Pharmacare Holdings Limited, B. Braun Melsungen AG, Fresenius SE & Co. KGaA and Pfizer Inc. are the major companies operating in the Global Anesthesia Drugs Market.
Which is the fastest growing region in Global Anesthesia Drugs Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Global Anesthesia Drugs Market?
In 2023, the North America accounts for the largest market share in the Global Anesthesia Drugs Market.
Anesthesia Drugs Industry Report
Statistics for the 2023 Anesthesia Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anesthesia Drugs analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.